Intra-Cellular Therapies, Inc.
ORGANIC COMPOUNDS

Last updated:

Abstract:

The disclosure relates to methods of administering comprising administration of inhibitors of phosphodiesterase 1 (PDE1) for the treatment and/or prophylaxis of renal disorders, such as chronic kidney disease. Related compounds and methods of making are further defined.

Status:
Application
Type:

Utility

Filling date:

21 Aug 2020

Issue date:

8 Sep 2022